PTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by Zacks Research

Posted by Stanley Muller on Aug 8th, 2026

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

A number of other research analysts have also recently commented on PTCT. Citigroup raised PTC Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $75.00 to $108.00 in a research note on Tuesday, June 9th. Cantor Fitzgerald boosted their price objective on PTC Therapeutics from $124.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, July 16th. Morgan Stanley upped their price objective on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Royal Bank Of Canada increased their target price on PTC Therapeutics from $82.00 to $85.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings upgraded PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $98.09.

Check Out Our Latest Stock Analysis on PTC Therapeutics

PTC Therapeutics Stock Up 3.5%

PTCT stock opened at $73.31 on Thursday. PTC Therapeutics has a 52 week low of $43.17 and a 52 week high of $90.87. The firm has a market capitalization of $6.12 billion, a P/E ratio of -126.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.56. The company has a fifty day simple moving average of $77.54 and a two-hundred day simple moving average of $72.55.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.68. The firm had revenue of $360.52 million during the quarter, compared to the consensus estimate of $298.63 million. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The firm’s revenue for the quarter was up 101.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.83) EPS. As a group, analysts anticipate that PTC Therapeutics will post 1.17 EPS for the current year.

Insider Activity at PTC Therapeutics

In other news, insider Neil Gregory Almstead sold 2,464 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $90.25, for a total transaction of $222,376.00. Following the completion of the sale, the insider owned 60,299 shares of the company’s stock, valued at approximately $5,441,984.75. The trade was a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary L. Smith sold 15,834 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $90.00, for a total value of $1,425,060.00. Following the completion of the transaction, the director directly owned 21,813 shares in the company, valued at approximately $1,963,170. This trade represents a 42.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 205,414 shares of company stock worth $16,774,162. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On PTC Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in PTC Therapeutics in the second quarter valued at about $1,139,089,000. Pallas Capital Advisors LLC purchased a new stake in shares of PTC Therapeutics during the second quarter valued at $263,000. Deutsche Bank AG acquired a new position in shares of PTC Therapeutics in the 2nd quarter valued at $24,218,000. State of Wyoming acquired a new position in shares of PTC Therapeutics in the 2nd quarter valued at $139,000. Finally, Summit Global Investments purchased a new position in PTC Therapeutics in the 2nd quarter worth $615,000.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.